IL6 and cancer: This interaction stimulates the release of inflammatory mediators, including interleukin-6 (IL-6), interleukin-17 (IL-17), and TNF-α, which foster a pro-tumorigenic microenvironment that enhances cancer cell proliferation and metastatic potential (44, 45).